Research and Markets: New Report Profiles Leading Central European Pharma Company; Zentiva

Business Wire, July 13, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c62615) has announced the addition of Zentiva Company Profile to their offering.

IMS Health's Company Profiles give you the authoritative insight into a company at a strategic and local level.

Each individual IMS Company Profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy.

* Critical analyses provided by an in-house expert team

* 90 full in-depth company profiles covering all major pharmaceutical companies worldwide including private companies

* Includes some Generic, Biotechnology and Drug Delivery companies

* Includes IMS Health sales data on products and therapies

* In depth product and R&D reviews, including clinical trial, lifecycle management, competition and analysts forecasts

* Mergers and acquisitions; licensing agreements

* Forecasts and comments from leading financial analysts

* Companies' conferences, annual reports, press releases

* Comments from stockbrokers/analysts reports used throughout the profile and especially within the Strategy, Financial and Product sections.

Corporate Structure

Strategy statement

Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:

* M&A

* Regional strategies

* Therapeutic focus

* R&D strategy

* Licensing activities

* Commentary on future prospects, including brokers' overviews

* Interview with a key person (where available), including quotes and opinions

* Forecasting table (top 30 companies only), showing events with major potential impact

Financial Review

Company sales performance as well as analyst's comments and forecasts.

Company Sales Performance:

* Financial review

* Latest results

* Sales by geographical region & leading country

* Sales by country and subsidiary

* Analysis comments

Product Portfolio

Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.

The section shows:

* Summary table of products facing patent expiry.

* Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.

R&D Pipelines

Comprehensive details of the projects that the company has in its R&D pipeline including:

* Research pipeline summary table.

* Introduction to the R&D activities of the company.

* Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.

* Quotes from senior personnel gleaned from conferences may also be included in this section when available.

Key figures

* Sales by business segment.

* Sales by geographical region.

Analyst figures

IMS Sales data

* Pharmaceutical sales by geographical region and leading countries.

* Top 5 third level therapeutic classes.

* Leading international products

* Pharmaceutical sales analysis by age

Employee data

Licensing/Co-Marketing Agreements

Displayed in a tabular format to enable you to have "at a glance" review of the licensing activities of the company.

Three sections are available to review licensing activities:

* Marketed products

* R&D pipeline products

* General research collaborations, including combinatorial chemistry, proprietary technologies etc.

Major Events

Summary of the major events that have affected the company. This includes recent and historical events.

Two sections

* Mergers and Acquisitions

* Other major events

Events are organised in chronological order.

Subsidiaries listing

Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.

For more information visit http://www.researchandmarkets.com/reports/c62615